Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study

• DOI: 10.3389/fimmu.2022.939311
• Publication Date: 2022-08-12T05:21:58Z
• Authors: Qianhui Hua; Hangjie Zhang; Pingping Yao; Nani Xu; Yisheng Sun; Hangjing Lu; Fang Xu; Yuting Liao; Juan Yang; Haiyan Mao; Yanjun Zhang; Hanping Zhu; Xiaowei Hu; Huakun Lv; Jianmin Jiang
• Keywords: Seroconversion; Inactivated vaccine

Background Owing to the coronavirus disease 2019 (COVID-19) pandemic and emergency use of different types COVID-19 vaccines, there is an urgent need consider effectiveness persistence vaccines. Methods We investigated immunogenicity CoronaVac Covilo, two inactivated vaccines against that each contain severe acute respiratory syndrome 2 (SARS-CoV-2). The levels neutralizing antibodies live SARS-CoV-2 inhibition rates pseudovirus, as well immunoglobulin (Ig)G IgM responses towards spike (S) nucleocapsid (N) protein at 180 days after two-dose vaccination were detected. Results Covilo induced similar antibody responses. Regarding SARS-CoV-2, 77.9% vaccine recipients 78.3% (aged 18–59 years) seroconverted by 28 second dose. SARS-CoV-2-specific antibodies, 97.1% 95.7% a pseudovirus Delta variant significantly lower compared with those wildtype SARS-CoV-2. Associated participant characteristics levels, persons in older age group basic disease, especially chronic tended have anti-SARS-CoV-2 seroconversion rates. Conclusion Antibodies elicited these appeared wane following their peak dose, but they persisted detectable through 6 months was than which suggests attention must be paid protective effectiveness, its persistence, on variants.